--- title: "Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori" type: "News" locale: "en" url: "https://longbridge.com/en/news/282752451.md" description: "Xuanzhu Biopharmaceutical Co., Ltd. has received approval from China's drug regulator to initiate a Phase III trial for its Anaprazole Sodium Enteric-coated Tablets aimed at eradicating Helicobacter pylori. The study will involve 556 adults and compare the efficacy of anaprazole-based therapy against esomeprazole. This trial is part of Xuanzhu's strategy to expand its presence in the gastrointestinal market, targeting a treatment market projected to reach RMB5.5 billion by 2024. The company aims to enhance its role in digestive disease treatments and capitalize on the growing demand for safer proton pump inhibitors in China." datetime: "2026-04-14T22:40:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282752451.md) - [en](https://longbridge.com/en/news/282752451.md) - [zh-HK](https://longbridge.com/zh-HK/news/282752451.md) --- # Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori ### Claim 30% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Xuanzhu Biopharmaceutical Co., Ltd. Class H ( (HK:2575) ) has provided an announcement. Xuanzhu Biopharmaceutical has received approval from China’s drug regulator to launch a Phase III trial of a bismuth-containing quadruple therapy using its Anaprazole Sodium Enteric-coated Tablets for eradicating Helicobacter pylori. The randomized, double-blind study will enroll 556 adults and compare anaprazole-based therapy with an esomeprazole-based regimen, assessing eradication rates and safety. Helicobacter pylori infection remains highly prevalent in China, and Frost & Sullivan estimates the related treatment market at RMB5.5 billion in 2024, potentially more than doubling by 2035. The new indication could significantly broaden Anaprazole Sodium’s clinical use, deepen Xuanzhu’s presence in digestive disease treatment, and support its long-term commercialization strategy as it builds on its first approved indication for duodenal ulcer and ongoing reflux esophagitis trials. By advancing this pivotal study, the company is directly targeting a fast-growing segment of the gastrointestinal market and seeking to leverage the drug’s differentiated metabolism profile to capture share from older proton pump inhibitors. The move underscores Xuanzhu’s ambition to cement its position as a domestic innovator in gastroenterology and enhance value for patients and stakeholders in China’s large and expanding H. pylori treatment space. **More about Xuanzhu Biopharmaceutical Co., Ltd. Class H** Xuanzhu Biopharmaceutical Co., Ltd. is a China-based innovative drug developer focused on gastrointestinal and digestive disease treatments. Its key product Anaprazole Sodium, a Class 1 domestically developed proton pump inhibitor marketed as An Jiu Wei, targets conditions such as duodenal ulcer and is designed to reduce drug-drug interactions and suit the genetic profile of Chinese patients. With a growing portfolio that includes late-stage studies in reflux esophagitis, the company is positioning itself as a leading local player in the proton pump inhibitor market. By emphasizing safer options for patients on multiple medications and those with renal impairment, Xuanzhu aims to strengthen its role in China’s expanding gastrointestinal therapeutics market. **Average Trading Volume:** 699,401 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** HK$16.76B For an in-depth examination of 2575 stock, go to TipRanks’ Overview page. ### Related Stocks - [02575.HK](https://longbridge.com/en/quote/02575.HK.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) ## Related News & Research - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)